Scholarlink

Purpose <p>This study aimed to explore whether different controlled ovarian hyperstimulation (COH) protocols were associated with the incidence of aneuploid blastocysts in cycles undergoing preimplantation genetic testing for aneuploidy (PGT-A).</p> Methods <p>A retrospective analysis was conducted on 5525 blastocysts from 1722 women (21–37&#xa0;years old) who underwent PGT-A cycles utilizing next-generation sequencing (NGS). The cohorts included 240 cycles employing the gonadotropin-releasing hormone agonist (GnRH-a) short protocol, 698 cycles using the GnRH-a long protocol, and 784 cycles utilizing the GnRH antagonist (GnRH-ant) protocol.</p> Results <p>A significantly elevated rate of blastocyst aneuploidy was observed in the GnRH-a short protocol group relative to both the long protocol and antagonist protocol groups (44.05% vs. 36.00% vs. 37.90%). Multivariable regression analyses, with the GnRH-a long protocol serving as the reference category, indicated that the short protocol was independently correlated with higher aneuploidy rates (OR = 1.30, 95% CI 1.06–1.60, <i>P</i> = 0.012). This association was particularly evident among younger patients (&lt; 35&#xa0;years) possessing preserved ovarian reserve (AMH ≥ 1.2&#xa0;ng/mL) (OR = 1.38, 95% CI 1.02–1.87, <i>P</i> = 0.036). Although non-significant, the short protocol also trended towards a higher aneuploidy rate compared to the antagonist protocol (OR = 1.12, 95% CI 0.89–1.41, <i>P</i> = 0.32).</p> Conclusions <p>The findings suggest that, in the population studied (21–37&#xa0;years), the GnRH-a short protocol is associated with a higher incidence of blastocyst aneuploidy compared to the long protocol, particularly in younger individuals (&lt; 35&#xa0;years) with normal ovarian reserve (AMH ≥ 1.2&#xa0;ng/mL). These results highlight the need for tailored COH protocol selection based on patient characteristics in PGT-A cycles.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of controlled ovarian hyperstimulation protocols on aneuploidy of preimplantation blastocysts in women aged 21–37 years old

  • 期刊论文

  • 发表日期：

    2025年9月15日

查看全文
  • Ye Zheng,
  • Wenyu Liu,
  • Min Su,
  • Shiheng Zhu,
  • Xiufang Li,
  • Hongqiang Xie,
  • Chunzi Lyu,
  • Wei Zhou,
  • Tianxiang Ni,
  • Qian Zhang,
  • Yuan Gao,
  • Junhao Yan

摘要

Purpose

This study aimed to explore whether different controlled ovarian hyperstimulation (COH) protocols were associated with the incidence of aneuploid blastocysts in cycles undergoing preimplantation genetic testing for aneuploidy (PGT-A).

Methods

A retrospective analysis was conducted on 5525 blastocysts from 1722 women (21–37 years old) who underwent PGT-A cycles utilizing next-generation sequencing (NGS). The cohorts included 240 cycles employing the gonadotropin-releasing hormone agonist (GnRH-a) short protocol, 698 cycles using the GnRH-a long protocol, and 784 cycles utilizing the GnRH antagonist (GnRH-ant) protocol.

Results

A significantly elevated rate of blastocyst aneuploidy was observed in the GnRH-a short protocol group relative to both the long protocol and antagonist protocol groups (44.05% vs. 36.00% vs. 37.90%). Multivariable regression analyses, with the GnRH-a long protocol serving as the reference category, indicated that the short protocol was independently correlated with higher aneuploidy rates (OR = 1.30, 95% CI 1.06–1.60, P = 0.012). This association was particularly evident among younger patients (< 35 years) possessing preserved ovarian reserve (AMH ≥ 1.2 ng/mL) (OR = 1.38, 95% CI 1.02–1.87, P = 0.036). Although non-significant, the short protocol also trended towards a higher aneuploidy rate compared to the antagonist protocol (OR = 1.12, 95% CI 0.89–1.41, P = 0.32).

Conclusions

The findings suggest that, in the population studied (21–37 years), the GnRH-a short protocol is associated with a higher incidence of blastocyst aneuploidy compared to the long protocol, particularly in younger individuals (< 35 years) with normal ovarian reserve (AMH ≥ 1.2 ng/mL). These results highlight the need for tailored COH protocol selection based on patient characteristics in PGT-A cycles.